Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact

Usage Information

Vaccines targeting the inflammasome protein ASC reduce inflammation and downstream pathology in multiple disease models
Jonathan Hulse, Zachary Villaseñor, Samuel Kress, Kathryn Sánchez, Julianne Peabody, Kimberly A. Morrissey, Alan McNolty, Benjamin Lantz, Laura Gonzalez Bosc, Judy L. Cannon, Seth Daly, Bryce Chackerian, Kiran Bhaskar
Jonathan Hulse, Zachary Villaseñor, Samuel Kress, Kathryn Sánchez, Julianne Peabody, Kimberly A. Morrissey, Alan McNolty, Benjamin Lantz, Laura Gonzalez Bosc, Judy L. Cannon, Seth Daly, Bryce Chackerian, Kiran Bhaskar
View: Text | PDF
Research In-Press Preview Immunology Inflammation Neuroscience

Vaccines targeting the inflammasome protein ASC reduce inflammation and downstream pathology in multiple disease models

  • Text
  • PDF
Abstract

The inflammasome is an innate immune complex responsible for aberrant interleukin-1β (IL-1β) signaling in numerous chronic inflammatory diseases, including gout and Alzheimer’s disease. The inflammasome is composed of several proteins, including the apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC). We developed vaccines targeting various regions of ASC using a Qβ virus-like particle (VLP) platform to assess the efficacy of anti-ASC antibodies for inhibiting inflammasome activity. Using a mouse model of gout, we assessed seven vaccines targeting mouse ASC for their ability to reduce inflammasome activation and neutrophil responses. Three vaccines targeting different regions of the ASC protein (pyrin domain, linker region, and the caspase activation and recruitment domain) successfully targeted ASC, reduced IL-1β, and reduced neutrophil activation. Combining these three vaccines into one cocktail vaccine yielded similar efficacy in the gout model with a favorable safety profile. The combined ASC vaccine also reduced inflammasome levels and pathologically phosphorylated tau in a transgenic mouse model of tauopathy and did not significantly impair host immune responses to bacterial or viral infections. Thus, Qβ-VLP vaccines against ASC can neutralize pathological inflammasome activity across multiple inflammatory disease models.

Authors

Jonathan Hulse, Zachary Villaseñor, Samuel Kress, Kathryn Sánchez, Julianne Peabody, Kimberly A. Morrissey, Alan McNolty, Benjamin Lantz, Laura Gonzalez Bosc, Judy L. Cannon, Seth Daly, Bryce Chackerian, Kiran Bhaskar

×

Usage data is cumulative from October 2026 through October 2026.

Usage JCI PMC
Text version 49 0
PDF 33 0
Supplemental data 20 0
Citation downloads 26 0
Totals 128 0
Total Views 128

Usage information is collected from two different sources: this site (JCI) and Pubmed Central (PMC). JCI information (compiled daily) shows human readership based on methods we employ to screen out robotic usage. PMC information (aggregated monthly) is also similarly screened of robotic usage.

Various methods are used to distinguish robotic usage. For example, Google automatically scans articles to add to its search index and identifies itself as robotic; other services might not clearly identify themselves as robotic, or they are new or unknown as robotic. Because this activity can be misinterpreted as human readership, data may be re-processed periodically to reflect an improved understanding of robotic activity. Because of these factors, readers should consider usage information illustrative but subject to change.

Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts